3066 The evaluation of intravenous magnesium supplementation in the prophylaxis of cisplatin-induced hypomagnesaemia

Anvari, K.; Tousi, M. Seilanian; Mirsadraee, Majid

doi:10.1016/s1359-6349(09)70665-2

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cisplatin-induced hyponatremia was more common in females and patients with older age group (Tables 3 and 4). Hamdi et al (18) reported 69% incidence of cisplatininduced hyponatremia, on contrary Arunkumar et al (13) reported an increase in serum sodium level. They concluded that, opined that this may be due to infusing normal saline before cisplatin chemotherapy.…”

Section: Discussionmentioning

confidence: 96%

“…Female suffer more as compared to male (66, P = 0.003; Tables 2 and 5), In contrast, Markman et al (17) reported the incidence of cisplatin-induced hypomagnesemia in 89% of ovarian cancer but their sample size was small. Direct injury to renal magnesium reabsorption in ascending loop of Henle, and distal tubule, is the possible mechanism behind the cisplatin-induced hypomagnesemia (18).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Frequency of electrolyte imbalance associated with cisplatin in oral cancer patients; a tertiary care experience from Pakistan

2018

View full text Add to dashboard Cite

Introduction: Electrolyte imbalance associated with cisplatin is quite prevalent, and increase morbidity in cancer patients. Objectives: To determine the frequency of electrolyte imbalance associated with cisplatin in oral cancer patients. Patients and Methods: Oral cancer patients of more than 16 years of age, who received cisplatin-based cancer chemotherapy, were monitored for electrolyte imbalance (Na, K, Ca and Mg). Patients who were as the known cases of kidney disease (acute or chronic) or those having electrolyte imbalance prior to start of chemotherapy were excluded. Primary outcome was to determine electrolyte imbalance. Results: Among 98 patients, 90 patients developed electrolyte imbalance to cisplatin chemotherapy. The observed electrolyte imbalance included hyponatremia, hypokalemia, hypomagnesemia and hypocalcaemia. Hypokalemia is found to be the most common electrolyte to be affected in the patients (91.8%), whereas hypocalcemia in 88.7%, hypomagnesemia in 67.34% is also observed. Mild hyponatremia is also observed less frequently in 67% of patients. Conclusion: Cisplatin-based chemotherapy has a high potential to cause electrolyte imbalance. Most of the abnormalities were of milder nature and not associated with symptoms. The common electrolyte abnormalities such as hypokalemia, hypocalcemia and hypomagnesemia were statistically significant, but hyponatremia was not statistically significant.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Frequency of electrolyte imbalance associated with cisplatin in oral cancer patients; a tertiary care experience from Pakistan

2018

View full text Add to dashboard Cite

show abstract

“…Another mechanism proposed for hypomagnesemia is decreased intestinal absorption. 4,[6][7][8] In attempts to overcome cisplatin associated hypomagnesemia and hypokalemia, studies have reviewed the role of electrolytesupplementation in various phases of cisplatin administration including pre-, during, and posthydration. It is suggested that magnesiumsupplemented hydration therapy not only replenishes magnesium but also impacts a transporter expression to reduce the amount of cisplatin introduced to the tubular cells.…”

Section: Discussionmentioning

confidence: 99%

Characterizing the impact of magnesium and potassium-supplemented hydration with cisplatin and the subsequent electrolyte replacement requirements

Uhm

Meszaros

Hammonds

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

Background Cisplatin-associated electrolyte dysregulation is a prevalent therapy-related adverse effect. There are numerous electrolyte-supplemented hydration regimens that have been evaluated, however these studies focused on the development of nephrotoxicity. The objective of this study was to characterize the impact of magnesium and potassium-supplemented hydration during cisplatin administration on subsequent magnesium and potassium imbalances. Methods A single-region retrospective study from central Texas at Baylor Scott & White Cancer Clinics who were treated with two or more cycles of cisplatin were included. Standard hydration for this study was defined as normal saline before and after cisplatin along with potassium chloride 10 mEq and magnesium sulfate 1 g added to the cisplatin bag. Results A total of 477 patients were included in the study with376 patients receiving the standard hydration. Overall, 17 percent of patients experienced a potassium level below 3.5 mEq/L, but no major depletion was observed. Thirty-three percent of the patients experienced a magnesium level below 1.8 mg/dL, and time to first rescue magnesium supplementation was 4 weeks. Conclusion Our study demonstrated despite routine magnesium and potassium supplementation in hydration, magnesium imbalances were observed. Potassium levels post cisplatin administration were maintained with minimal routine supplementation in hydration.

show abstract

3066 The evaluation of intravenous magnesium supplementation in the prophylaxis of cisplatin-induced hypomagnesaemia

Cited by 2 publications

References 0 publications

Frequency of electrolyte imbalance associated with cisplatin in oral cancer patients; a tertiary care experience from Pakistan

Frequency of electrolyte imbalance associated with cisplatin in oral cancer patients; a tertiary care experience from Pakistan

Characterizing the impact of magnesium and potassium-supplemented hydration with cisplatin and the subsequent electrolyte replacement requirements

Contact Info

Product

Resources

About